CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


RadspherinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug658 Convalescent plasma Wiki 0.25

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D000077216 Carcinoma, Ovarian Epithelial NIH 1.00
D010534 Peritoneal Neoplasms NIH 1.00
D010051 Ovarian Neoplasms NIH 0.71
D002277 Carcinoma NIH 0.45

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0100615 Ovarian neoplasm HPO 0.71
HP:0030731 Carcinoma HPO 0.45

There is one clinical trial.

Clinical Trials


1 A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following CRS

RAD-18-001 is a First-In-Man, Dose Escaltion study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose Limiting Toxicicities (which will stop the dose escalation), this will be the recommended dose for further exploration. Acceptability of up to 7 MBq gives the opportunity to explore the doses of the dose escalation split into two administrations, and given as two separate injections 1 week apart. Split doses of 1, 2 and 3.5 MBq will be administered as two injections. Each subject will be followed until disease progression (in the abdominal cavity), or for 12 months after the administration of Radspherin® (whichever comes first).

NCT03732768 Peritoneal Carcinomatosis Ovarian Cancer Drug: Radspherin
MeSH:Ovarian Neoplasms Carcinoma, Ovarian Epithelial Carcinoma Peritoneal Neoplasms
HPO:Carcinoma Ovarian neoplasm

Primary Outcomes

Description: To investigate safety and toxicity of Radspherin®

Measure: Number of participants with Dose Limiting Toxicities as assessed by CTCAE v5.0.

Time: 12 months

Description: To determine the MTD of Radspherin®, among the four suggested doses 1, 2, 4 and 7 MBq, as a single intraperitoneal (IP) injection and two repeated IP injections following cytoreductive surgery (CRS)

Measure: Maximum Tolerated Dose (MTD)

Time: 21 days


Related HPO nodes (Using clinical trials)